377 reports of this reaction
5.6% of all ERIBULIN MESYLATE reports
#2 most reported adverse reaction
MALIGNANT NEOPLASM PROGRESSION is the #2 most commonly reported adverse reaction for ERIBULIN MESYLATE, manufactured by BSP Pharmaceuticals SpA. There are 377 FDA adverse event reports linking ERIBULIN MESYLATE to MALIGNANT NEOPLASM PROGRESSION. This represents approximately 5.6% of all 6,741 adverse event reports for this drug.
Patients taking ERIBULIN MESYLATE who experience malignant neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT NEOPLASM PROGRESSION is moderately reported among ERIBULIN MESYLATE users, representing a notable but not dominant share of adverse events.
In addition to malignant neoplasm progression, the following adverse reactions have been reported for ERIBULIN MESYLATE:
The following drugs have also been linked to malignant neoplasm progression in FDA adverse event reports:
MALIGNANT NEOPLASM PROGRESSION has been reported as an adverse event in 377 FDA reports for ERIBULIN MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT NEOPLASM PROGRESSION accounts for approximately 5.6% of all adverse event reports for ERIBULIN MESYLATE, making it one of the most commonly reported side effect.
If you experience malignant neoplasm progression while taking ERIBULIN MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.